Beyond Air (XAIR) Asset Writedowns and Impairment (2024 - 2025)

Beyond Air (XAIR) reported Asset Writedowns and Impairment of -$157000.0 for Q1 2025, down 196.32% sequentially from $163000.0 in Q4 2024.

Beyond Air (XAIR) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends

Beyond Air (XAIR) has 2 years of Asset Writedowns and Impairment data on file, last reported at -$157000.0 in Q1 2025.

For the quarter ending Q1 2025, Asset Writedowns and Impairment changed N/A year-over-year to -$157000.0; the trailing twelve-month figure through Mar 2025 stood at $6000.0 (changed N/A YoY), and the FY2026 full-year result was $672000.0, up 279.66% from the prior year.
Asset Writedowns and Impairment eased to -$157000.0 in Q1 2025, from $163000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $163000.0 in Q4 2024 to a low of -$157000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn
8	Smith & Nephew	26.99 Bn	26.41 Bn	-
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn
10	Beyond Air	2.23 Mn	-10.13 Mn	94,000.00

Download Data